A prospective study in a total of 105 patients at a high risk of OHSS concluded that GnRH-ant administration for three days was effective in reducing the moderate-to-severe OHSS incidence and inducing a faster regression of OHSS symptoms (11/61 (18.03%) vs. 13/35 (37.14%), p = 0.03) [47]. Here, GNRH1 is linked to ovarian hyperstimulation syndrome.